For the quarter ended September 2026, Glaukos (GKOS Quick QuoteGKOS - Free Report) reported revenue of $211.03 million, up 58% over the same period last year. EPS came in at $0.47, compared to -$0.16 in the year-ago quarter.

The reported revenue represents a surprise of +24.99% over the Zacks Consensus Estimate of $168.84 million. With the consensus EPS estimate being -$0.12, the EPS surprise was +491.67%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Glaukos performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues by geography- United States: $174.85 million versus $132.79 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +72.4% change.
• Revenues by product category- United States- Glaucoma: $118.64 million versus the four-analyst average estimate of $112.85 million. The reported number represents a year-over-year change of +46.8%.
• Revenues by product category- International- Corneal Health: $2.83 million versus $2.7 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
• Revenues by geography- International: $36.18 million versus $35.5 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.8% change.
• Revenues by product category- International- Glaucoma: $33.36 million compared to the $32.8 million average estimate based on four analysts. The reported number represents a change of +13.5% year over year.
• Revenues by product category- United States- Corneal Health: $56.21 million versus the four-analyst average estimate of $19.93 million. The reported number represents a year-over-year change of +172.3%.
• Net Sales- Corneal Health: $59.04 million versus the five-analyst average estimate of $23.1 million. The reported number represents a year-over-year change of +153.4%.
• Net Sales- Glaucoma: $151.99 million versus $146.32 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +37.9% change.

View all Key Company Metrics for Glaukos here>>>

Shares of Glaukos have returned +14.3% over the past month versus the Zacks S&P 500 composite's -0.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.